Stock ALBO ALBIREO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ALBIREO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Albireo Pharma, Inc. - FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome
AQ
ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome
AQ
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO
BU
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO
BU
ALERT: The M&A Class Action Firm Announces the Investigation of Albireo Pharma, Inc. - ALBO
PR
Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsen
PR
ALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to Shareholders
BU
Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases - Form 8-K
PU
ALBIREO PHARMA, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
PU
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
AQ
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer and Craig Hopkinson, M.D., to Board of Directors
AQ
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
ALBIREO PHARMA, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors
AQ
Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2
GL
Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALBO Stock
  4. News Albireo Pharma, Inc.
  5. Press Releases